EU/3/12/1060

About

On 8 November 2012, orphan designation (EU/3/12/1060) was granted by the European Commission to Takeda Global Research and Development Centre (Europe) Ltd, United Kingdom, for ixazomib for the treatment of systemic light chain amyloidosis.

In November 2013, Takeda Global Research and Development Centre (Europe) Ltd changed name to Takeda Development Centre Europe Ltd.

The sponsorship was transferred to Takeda Pharma A/S, Denmark, in March 2015.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
Ixazomib
Disease / condition
Treatment of systemic light chain amyloidosis
Date of first decision
08/11/2012
Outcome
Positive
EU designation number
EU/3/12/1060

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Hovedstaden
Danmark
Tel: +45 4677 1111
E-mail: kristina.stovring@takeda.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating